Peptide Initiative

Peptides · Peptide comparison

ARA-290 (Cibinetide) vs BPC-157

A peptide that awakens your body's natural repair system to heal damaged nerves and reduce pain

The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.

  • Healing & Recovery
  • Healing & Recovery

At a glance

Quick comparison

Dose rangeARA-290 (Cibinetide)4–4 mgBPC-157250–500 mcg
FrequencyARA-290 (Cibinetide)Once dailyBPC-157Once daily
AdministrationARA-290 (Cibinetide)Subcutaneous injectionBPC-157Subcutaneous injection
Cycle lengthARA-290 (Cibinetide)Ongoing/indefiniteBPC-1574-6 weeks
Onset speedARA-290 (Cibinetide)Moderate (1-2 weeks)BPC-157Moderate (1-2 weeks)
Evidence levelARA-290 (Cibinetide)Moderate human trials (Phase 1-2)BPC-157Strong preclinical (extensive animal studies)

Efficacy

Benefit ratings

Nerve Regeneration

ARA-290 (Cibinetide)95%
BPC-157No recorded rating

Pain Management

ARA-290 (Cibinetide)85%
BPC-157No recorded rating

Tissue Protection

ARA-290 (Cibinetide)90%
BPC-157No recorded rating

Primary Benefit

ARA-290 (Cibinetide)No recorded rating
BPC-15785%

Secondary Benefit

ARA-290 (Cibinetide)No recorded rating
BPC-15778%

Additional Benefit

ARA-290 (Cibinetide)No recorded rating
BPC-15772%

Technical data

Compound specifications

ARA-290 (Cibinetide)

Molecular formula
C51H84N16O21
Molecular weight
1257.31 g/mol
Half-life
Approximately 1-2 hours in circulation, but cellular effects last much longer
Bioavailability
Subcutaneous: ~100% (complete absorption); Intravenous: Immediate
CAS number
1208243-50-8

BPC-157

Molecular formula
C62H98N16O22
Molecular weight
1419.53 g/mol
Half-life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS number
137525-51-0

Protocols

Dosing compared

ARA-290 (Cibinetide)

Subcutaneous

  • 1 mgOnce daily · 28 daysLowest dose tested in the phase 2 sarcoidosis nerve study. A good starting point while watching how the body responds [1].
  • 4 mgOnce daily · 28 daysThe 4 mg dose gave the strongest nerve-fiber regrowth and pain relief in the trial — better than the higher 8 mg dose [1][2].
  • 8 mgOnce daily · 28 daysHighest daily dose studied in the sarcoidosis trial. It was safe but did not beat 4 mg for nerve outcomes [1].

Intravenous

  • 2 mgThree times weekly · 4 weeksAn earlier sarcoidosis pilot gave 2 mg into a vein three times a week and saw improved nerve symptoms [6].

BPC-157

Subcutaneous

  • 250 mcgOnce daily · 1-2 weeksA common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
  • 250-500 mcgTwice daily · 4-6 weeksCommonly used range for tissue and tendon recovery in research practice [1][3].
  • 500 mcgTwice daily · 6-8 weeksUpper end used in practice for more demanding acute injuries [1][3].

Applications

Best suited for

ARA-290 (Cibinetide)

Treating small fiber neuropathy
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on treating small fiber neuropathy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing neuropathic pain from diabetes or sarcoidosis
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on managing neuropathic pain from diabetes or sarcoidosis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting nerve regeneration after injury
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on supporting nerve regeneration after injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing chronic inflammation
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on reducing chronic inflammation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

BPC-157

Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair [1][7]
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions [1][11] - derived from gastric juice, it has a natural affinity for digestive tissue [3][5]
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression [8]
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties [9][10]
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms [2]

Safety profile

Side effects

ARA-290 (Cibinetide)

Common

  • Injection Site Reactions
  • Headache
  • Dizziness

Uncommon

  • Elevated Blood Pressure
  • Fatigue

Serious

  • Blood Clot Formation

BPC-157

Common

  • Injection site redness
  • Mild nausea
  • Dizziness

Uncommon

  • Headache
  • Fatigue
  • Hot/cold sensations

Serious

  • Allergic reaction

Research status

Safety & evidence

ARA-290 (Cibinetide)

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Not FDA approved
Safety overview
ARA-290 is a synthetic innate repair receptor agonist that has completed Phase 2 clinical trials for small fiber neuropathy and is under active development. Animal toxicology studies show a good safety margin with no organ damage or cytotoxicity at doses far exceeding therapeutic levels. Early clinical data from Phase 2 trials demonstrate tolerability with mild injection site reactions and transient headache as primary concerns. However, immunogenicity remains a potential risk with repeated dosing of synthetic peptides, requiring anti-drug antibody monitoring. Long-term safety data beyond 12 weeks does not yet exist.

Contraindications

  • Polycythemia vera or erythrocytosis
  • Uncontrolled hypertension
  • Pregnancy or breastfeeding
  • Known hypersensitivity to peptides
  • Concurrent use with certain cancer medications

BPC-157

Evidence level
Strong preclinical (extensive animal studies)
FDA status
Research compound
Safety overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. [5] No FDA approval exists. [4][6] Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. [4][5] Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. [2][4] The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. [6][7] Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.

Contraindications

  • Pregnancy
  • Breastfeeding
  • Active cancer
  • History of cancer

Decision guide

Which is right for you?

ARA-290 (Cibinetide)

Choose ARA-290 (Cibinetide) if…

  • Treating small fiber neuropathy
  • Managing neuropathic pain from diabetes or sarcoidosis
  • Supporting nerve regeneration after injury
  • Reducing chronic inflammation

BPC-157

Choose BPC-157 if…

  • Injury recovery
  • Post-surgery healing
  • Chronic pain management
  • Gut health